New Drug Candidate Prolongs The Lives Of Pancreatic Cancer Patients

1 Posts | Page(s): 1 

New Drug Candidate Prolongs The Lives Of Pancreatic Cancer Patients

by Kayle on Thu Jul 30, 2009 12:00 AM

Quote | Reply

Found this article and thought y'all would be interested.

New Drug Candidate Prolongs The Lives Of Pancreatic Cancer Patients

ScienceDaily (July 21, 2009) — Every year, 42,000 Americans are diagnosed with pancreatic cancer. Few live very long, and less than 5% are still alive five years after diagnosis.

There's new hope, though, from the lab of Prof. Yoel Kloog, dean of TAU's Faculty of Life Sciences. His drug compound Salirasib has shown positive results against pancreatic cancer and recently passed Phase I/II clinical trials. The drug, given in combination with gemcitabine, the standard drug used to combat pancreatic cancer, almost doubled the life expectancy of those who received it.

"In our study, the mean survival of pancreatic cancer patients was 10.8 months — better by far than the 6.2 months with gemcitabine alone," says Prof. Kloog, who recently presented the results to a meeting of the American Society of Clinical Oncology. His basic research offers the promise of a weapon to attack a broader range of mankind's most prevalent diseases, including lung, prostate and breast cancers as well as diabetes.

Rest of article at:

http://www.oncologyjournal.org/blogs/admin/603-new-drug-cand

 

 

 

1 Posts | Page(s): 1 
Subscribe to this message board discussion

Latest Messages

CancerCompass Poll

How often do you use a mobile device (e.g., iPhone, Blackberry, etc.) to access the internet?

We care about your feedback. Let us know how we can improve your CancerCompass experience.